‌

Minghui Pharmaceutical

Minghui Pharmaceutical is a Shanghai-based, late-stage biopharmaceutical company pioneering next-generation immuno-oncology therapies, including PD-1/VEGF bispecifics, IGF-1R inhibitors, and its lead B7-H3 ADC (MHB088C). In mid-2025, it secured USD 186 million licensing plus milestone and royalty payments from Qilu Pharma for Greater China rights.

Overview Structured Data Issues Contributors

minghuipharma.com

Is a

Company attributes

Industry

Biopharmaceutical

Location

B2X

CEO

Email Address

Phone Number

Full Address

Suite 6305, Building 6, 338 Jialilue Road, China

Investors

BioTrack Capital

TF Capital (Shanghai)

QiMing Venture Partners

Founded Date

2018

Total Funding Amount (USD)

131,000,000

Latest Funding Round Date

August 7, 2025

Latest Funding Type

Initial public offering (IPO)

Other attributes

Latest Funding Round Amount (USD)

131,000,000

No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more companies like Minghui Pharmaceutical

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.